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Detection of circulating prostate-specific antigen-positive cells in patients
with prostate cancer by flow cytometry and reverse transcription
polymerase chain reaction
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'Institutefor Cancer Studies, University ofSheffield Medical School, Sheffield S1O 2RX; 2University Urology Unit, Freeman
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Summary The presence of prostate-specific antigen (PSA)-positive cells has previously been demonstrated in
the peripheral blood of prostate cancer patients by flow cytometry (FC), but the identity of these cells has not
been established. In this study, the reverse transcriptase polymerase chain reaction (RT-PCR) was compared
with analytical FC in an attempt to detect and characterise these cells. Peripheral blood was obtained from 12
patients with newly diagnosed and untreated prostate cancer and five controls. Nine of the 12 patients with
prostate cancer (75%) had circulating PSA-positive cells as shown by FC. Only one of those patients (11.1%)
was found to express PSA mRNA by RT-PCR. The absence of PSA mRNA in the majority of samples
showing PSA-positive cells suggests that they do not represent haematogenous micrometastases. PSA-positive
cells in the blood could represent monocytes that express PSA, either following binding/phagocytosis of free
serum PSA or phagocytosis of tumour cells.
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reaction; flow cytometry
Prostate cancer is the third most common malignancy in men
in England and Wales, with over 10 000 new cases and 8000
deaths from the disease every year (OPCS, 1993). Over half
the patients present with locally advanced and/or metastatic
disease, and can be treated by palliative measures only. In
addition, once early tumours are detected, prognosis is
largely unpredictable by current investigative methods.
Clinicians are unable to predict disease progression and to
inform the patient whether his tumour is likely to progress,
or whether any form of treatment will alter the outcome.
New criteria to define the aggressive and metastatic potential
of early prostate cancer are needed, particularly in view of
the recent controversies and evidence from North American
studies questioning the benefits of radical surgery over
observation in early stage prostatic adenocarcinoma (Flem-
ing et al., 1993; Lu-Yao et al., 1993; Chodak et al., 1994).
Furthermore, even in cases where the disease appears to be
confined to the prostate, cancers are understaged in over 50%
of cases, with resulting positive surgical margins, extracap-
sular extension and potential treatment failure (Epstein et al.,
1993).
The formation of metastasis is a significant, rate-
determining event in the progression of cancer. It is a
complex, non-random phenomenon involving a cascade of
multisequential events, including tumour cell detachment
from the primary lesion into the blood and lymphatic
channels, survival of a selected population of malignant
cells in a hostile environment, extravasation at a chosen site
and the final formation of a secondary deposit (Poste and
Fidler, 1980).
In an attempt to isolate circulating tumour cells in
prostate cancer patients before their actual deposition at a
distant site and metastasis formation, we have previously
demonstrated the presence of circulating prostate-specific
antigen (PSA)-positive cells using monoclonal antibody
(MAb) staining for PSA and flow cytometric analysis
(Hamdy et al., 1992). Quantification of circulating PSA-
positive cells appeared to be a more sensitive predictor of
bone scan findings than serum PSA estimation. The
phenotype of these circulating PSA-positive cells however,
remains unclear, particularly in view of the large percentage
of these cells found in peripheral mononuclear cell
suspensions (up to 50% of separated cells). Recent studies
have demonstrated that haematogenous micrometastases can
be detected in some but not all patients with different stages
of prostate cancer using a reverse transcription polymerase
chain reaction (RT-PCR) based technique (Moreno et al.,
1992; Katz et al., 1994; Israeli et al., 1994). One study
suggested that 'molecular staging' of prostate cancer patients
by RT-PCR is superior to all other available staging
methods (Katz et al., 1994). Using a similar protocol,
involving reverse transcriptase PCR (RT-PCR) and South-
ern blotting, we have compared cytometric analysis of PSA-
positive circulating cells with RT-PCR in an attempt to
determine whether the peripheral circulating PSA-positive
cells represent a tumour cell population. The results and their
implications are discussed.
Patients, materials and methods
Patients
Twelve patients with histologically proven and untreated
carcinoma of the prostate (CaP) were studied. Three men
with benign prostatic hyperplasia and two healthy females
were used as controls. All men had three serial serum
prostate-specific antigen measurements (immunoradiometric
assay, CIS, UK) before prostatic manipulation, and patients
with CaP were staged by digital rectal examination,
transrectal ultrasonography, and technetium 99 m isotope
bone scanning. Six patients (50%) had evidence of skeletal
metastases as shown by a positive isotope bone scan. Two
patients had apparently localised disease, and the remaining
four had locally advanced tumours. Prostatic biopsies were
obtained transrectally and diagnosis was made by standard
histopathological criteria. All men with evidence of significant
symptomatic bladder outflow obstruction were treated by
transurethral resection of the prostate, and the tissue
obtained was histologically examined further. Patients with
metastatic CaP were treated by hormonal manipulation either
in the form of bilateral subcapsular orchidectomy or
Correspondence: FC Hamdy
Received 17 November 1995; revised 2 February 1996; accepted 22
February 1996administration of a luteinising hormone-releasing hormone
(LHRH) analogue. Men with tumours confined to the
prostate or locally advanced disease were treated by external
beam irradiation. Follow-up ranged from 10 to 21 months
(median 19 months). Of the six patients with metastases, one
had aggressive hormone refractory disease and died within
one week of inclusion in the study. All the other men were
alive and well at the last follow-up, having responded to the
various treatments administered. Patients' details are
summarised in Table I.
Sample preparation
Prostatic tissue Prostatic tissue was obtained from transrec-
tal core biopsies and resection specimens before definitive
therapy and histologically examined. Tissue samples were
collected in sterile cryovials, placed on ice and stored at
-80°C until processed. Specimens were minced into 1 mm
cubes with crossed scalpels then used for RNA extraction.
Benign prostatic hyperplastic (BPH) tissue was used as PSA-
positive control.
Prostate cancer cell line The prostatic cancer cell line
LNCaP (kindly provided by Dr M Harper, Tenovus
Institute, Cardiff, UK) was also used as a positive control
for PSA-positive cells. The cell line was grown in RPMI-1640
medium (Gibco, Paisley, UK) supplemented with 10% heat-
inactivated fetal calf serum (HIFCS) (Northumbria Biologi-
cals, Cramlington, UK) and cells were stored as a pellet of
107 cells at -80°C until processed.
Blood samples Ten millilitres of peripheral venous blood
was collected in EDTA vacutainers from male patients before
treatment, and from healthy female volunteers. Peripheral
blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation (J Prep, TechGen International,
London, UK) and subsequently tested for antigen expression
and ploidy status using flow cytometry. Cells used for RNA
extraction were stored as a pellet of 107 cells at -80°C until
processed.
MAb staining andflow cytometry
Approximately 106 PBMCs were stained with MAbs against
PSA and leucocyte common antigen (LCA) which was used
as a control (Dakopatts UK) by the two-stage method in
conjunction with fluorescein isothyocyanate (FITC)-conju-
gated goat anti-mouse f(ab')2 antibody (Caltag, Bradshaw
Biologicals, Leics, UK) (1 x 106 PBMC pellet). FITC-
Circuladng PSA-posiive cells in prostate cancer
EJ Fadlon et al !
401
conjugated goat anti-mouse negative control was included.
DNA ploidy status was measured by flow cytometry (Ortho
Diagnostic Orthocyte), using propidium iodide (DNA
CycleTest, Becton-Dickinson, Cowley, UK) and at least
10 000 cells analysed.
Oligonucleotide primers and probes
Oligonucleotide primers and probes were designed and
checked for specificity using the SEQNET facility (SERC,
Daresbury Laboratory, UK). The sequences used were as
follows:
Antisense PCR primer (exon 3):
5'-ACTCCTCTGGTTCAATGCTG-3'
Sense PCR primer (exon 2):
5'-TCATCCTGTCTCGGATTGTC-3'
Exon 3 probe:
5'-CCGACCCAGCAAGATCACGC-3'
These primers resulted in the amplification of a 426
basepair PCR product. Primers were synthesised by R &
D Systems (Europe), and the probe was synthesised in
the department using an Applied Biosystems 491 PCR-
Mate.
There is a high homology between PSA and the human
kallikrein (HMGK) genes (Riegmann et al., 1989). The
primers selected were specific for PSA and did not cross-react
with HMGK. Primer and magnesium concentrations were
titrated in order to avoid false-positives due to random
products. Both LNCaP and BPH tissues were used as the
positive controls for PSA expression. The amount of RNA
(1-5 Mg) was titrated for positive controls, both 1 and 5,g
of PBMC sample RNA were added to the reverse
transcriptase (RT) mix; at least one RNA-free control was
included for the RT procedure and at least two cDNA-free
controls for the PCR.
Labelling of oligonucleotide probes
Oligonucleotide probe (1 jg) was end-labelled with digox-
igenin dUTP by incubation at 370C for 3 h in a 50 ,l
reaction volume consisting of 1 x terminal deoxynucleotidyl
transferase (TdT) buffer (Life Technologies, Paisley, UK),
5 pM digoxigenin dUTP (Boehringer Mannheim, Lewes,
UK), 30 mM Tris HCl pH 6.8, 10 units of inorganic
pyrophosphatase (Sigma Chemical Co., Poole, UK) and 50
units of TdT (Life Technologies). The labelled oligonucleo-
tide was then stored at -200C until use.
Table I Summary of patients' details
Staging Grading sePSA PSA-positive Southern
Patients (TNM) (Gleason score) (ng ml-') cells (%) blot Treatment
1. CaP T3NxM0 6 81 9 Negative TURP+DXT
2. CaP T3NxMl 7 87 10 Negative TURP+HM
3. CaP T4NxMl 9 > 120 1.5 Negative TURP+HM
4. CaP T4NxM1 8 117 13 Negative HM
5. CaP T3NxMO 5 32 2 Negative TURP+DXT
6. CaP T2bNxMO 6 31 0 Negative DXT
7. CaP T3NxMO 8 35 3 Negative TURP+DXT
8. CaP T4NxMl 9 > 120 2 Positive TURP+HM
9. CaP T4NxM1 8 > 120 7 Negative DXT
10. CaP T2bNxMO 6 27 0 Negative DXT
11. CaP T3NxMO 9 83 2 Negative TURP+HM
12. CaP T4NxM1 7 >120 0 Negative TURP+HM
13. BPH - - 5 0 Negative TURP
14. BPH - - 9 0 Negative TURP
15. BPH - - 1.4 0 Negative TURP
16. HF - - 0.1 0 Negative
17. HF - - 0.1 0 Negative
CaP, carcinoma of the prostate; BPH, benign prostatic hyperplasia; HF, healthy female; sePSA, serum prostate-specific
antigen (120 ngml-, maximum measurement given by laboratory); TURP, transuretheral resection of the prostate; HM,
hormone manipulation; DXT, deep X-ray therapy.Circulating PSA-positive cells in prostate cancer
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Extraction of RNA
All solutions were pretreated with diethylpyrocarbonate
(DEPC) (Sigma) or made up with DEPC-treated water,
then autoclaved, and all glassware baked at 250°C for 4 h, to
ensure that the solutions were RNAase free. Total RNA was
extracted from 107 PBMCs by modification of the method of
Chomczynski and Saachi (1987) using an RNAzol B RNA
extraction kit (Biogenesis, Bournemouth, UK). The RNA
pellet was resuspended in 100 ,l of 0.5 mM EDTA then
precipitated overnight at -20°C in the presence of 50 MI 3 M
sodium acetate and 400 MI of absolute ethanol. The resulting
precipitate was washed once in 75% ethanol and air dried.
RNA was resuspended in 21 Ml of 0.5 mM EDTA. The
optical density of a 1 in 100 dilution was determined at
260 nm and 280 nm.
cDNA synthesis
Either 1 Mg or 5 Mg of RNA was adjusted to a final volume of
22 Ml using DEPC-treated water and 28 pl of reverse
transcriptase reaction mixture was added. This reaction
mixture was composed of 100 mM Tris HCl pH 8.3, 150 mM
potassium chloride, 6 mm magnesium chloride, 12 mM
dithiothreitol, 10 Mg random primer pd(N)6 (Pharmacia,
Milton Keynes, UK), 0.6 mM dNTPs (Pharmacia), and 400
units M-MLV reverse transcriptase (Life Technologies). The
reaction mixture was then incubated at 37°C for lh after
which the samples were used immediately or stored at -200C.
Polymerase chain reaction (PCR)
Five microlitres of cDNA preparation was added to the PCR
reaction mixture in a final volume of 50 MI containing the
following: 1 x Taq DNA polymerase incubation buffer
(Boehringer Mannheim), 0.2 mm each dATP, dCTP, dTTP
and dGTP (Pharmacia), 100 pmol of each oligonucleotide
primer and 1 unit Taq DNA polymerase (Pharmacia). The
mixture was overlaid with 50 Ml of mineral oil (Sigma) and
the amplification performed in a Perkin Elmer cycler as
follows: 2 min at 95°C; 35 cycles of 30 s at 95°C; 30 s at
55°C; 1 min 30 s at 720C (increasing by 6 s per cycle);
followed by a final 15 min extension period at 720C. The
reaction mixture was then stored at 40C until analysis.
cDNA-free negative controls were included for each RT-
PCR.
A single cell suspension of BPH tissue was prepared by
mincing with crossed scalpels followed by filtration through a
fine mesh. BPH cells were added to PBMCs obtained from
healthy females at the following ratios of BPH:PBMC:
1 102, 1: 103, 1: 104, 1: 105, 1 106. The PBH: PBMC cell
suspension was centrifuged and the supernatant discarded.
RNA was extracted from PBH-spiked PBMCs in order to
determine the sensitivity of the RT-PCR under the selected
assay conditions.
Analysis of PCR products
Chloroform (100 Ml) and 13 Ml of sample buffer (0.1%
bromophenol blue, 50% glycerol) were added to each tube
which was then shaken and centrifuged for 1 min at 7000 g.
Twenty-five millilitres of the upper layer was loaded onto a
1.5% agarose gel (Sea Kern GTG, Flowgen) containing TAE
buffer (40 mM Tris acetate, pH 8.3, 1 mM EDTA) immersed
in TAE running buffer. A 123 bp ladder (Life Technologies)
and digoxigenin-labelled markers VI (Boehringer Mannheim)
were included on each gel. Electrophoresis was performed at
100 V for 3 h, stained with 0.5 Mug ml-1 ethidium bromide for
30 min then examined under a UV light. The gel was washed
twice, for 10 min, in 0.4 M sodium hydroxide then blotted
overnight onto positively charged nylon membrane (Boeh-
ringer Mannheim). The blots were washed twice, for 10 min,
in 2 x TSB (1 x TSB = 150 mM sodium chloride, 15 mM Tris
HCl, pH 7.5), air dried and baked at 95°C for 40 min.
Blots were prehybridised at 55°C for at least 2 h in a
prehybridisation solution [4 x TSB, 0.1% Tween 20 (Sigma),
1% blocking reagent (Boehringer Mannheim), 100 g ml-'
sonicated salmon sperm DNA (Sigma), pH 7.5]. Digoxigen-
in-labelled oligonucleotide probe was added to the prehy-
bridisation solution at a final concentration of 2 ng ml-'
and hybridisation performed at 55°C for 16 h. The blots
were washed in decreasing TSB concentrations (4x TSB to
0.1 xTSB), at room temperature, 15 min per wash, and
again for 30 min, at room temperature, in a blocking
solution [1 x TBS (150 mM sodium chloride, 100 mM Tris
HCl, pH 7.5), 0.1% Tween 20, 1% blocking reagent]. Then
3.75 units of alkaline phosphatase-conjugated sheep anti-
digoxigenin IgG Fab fragment (Boehringer Mannheim) were
added and the incubation continued for a further 30 min.
Unbound antibody was removed by two 15 min washes in
1 x TBS followed by a 5 min equilibration in substrate buffer
(100 mM sodium chloride, 100 mM Tris HCl, pH 9.5). The
membrane was then soaked in substrate buffer containing
0.1 mg ml-1 Lumigen PPD (Boehringer Mannheim), placed
between two acetate sheets and exposed to preflashed
Hyperfilm MP (Amersham, Aylesbury, UK) at 37°C for
10-30 min.
Results
Flow cytometry, DNA and scatter analysis
Nine out of 12 patients with prostate cancer (75%) had
circulating PSA-positive cells ranging from 1.5-13% of
isolated PBMC populations as detected by FC. DNA
analysis of PBMCs showed all cells to be diploid. Patient 8
(Table I) showed an unusual scatter distribution for PBMCs,
and a cell population was detected of similar or greater size
to the monocyte population by normal scatter analysis
(Figure 1).
Detection of PSA mRNA by RT-PCR
Following the BPH spiking experiment under the conditions
outlined, we were able to detect one PSA-positive cell per 104
PBMCs by RT-PCR (two titrations, cDNA samples run at
least twice). The RT-PCR was 100-fold more sensitive than
the flow cytometric analysis threshold of one PSA-positive
cell per 100 PBMCs. Positive controls (BPH tissue) and
PBMC samples from negative controls and patients were
reverse transcribed and subjected to PCR amplification using
PSA-specific primer sequences. Following gel electrophoresis
and ethidium bromide staining, a PCR product correspond-
ing to a 426 bp fragment was detectable in all positive
controls, but not in the negative controls or patient PBMC
samples. For more sensitive detection, the gels were blotted
and hybridised with the antisense oligonucleotide probe
corresponding to a unique sequence of exon 3 (see Materials
and methods). This allowed the detection of a band of426 bp
in a single patient sample (Figure 2b). This sample was
obtained from patient 8 (Table I) who had an aggressive,
poorly differentiated locally advanced and metastatic tumour
(T4NxM1 Gleason score 9) which did not respond to
hormone manipulation, and also demonstrated an unusual
PBMC scatter analysis (illustrated in Figure la). RT-PCR
for LNCaP cells was carried out as a second positive control
with 1-5 Mg of total RNA. Products were detected for all
RNA concentrations. LNCaP cells and tissue extracts were
shown to express up to three bands; controls for PBMCs,
cDNA synthesis, PCR and RNAzol were all negative. Figure
2a shows negative (female PBMCs), positive controls
(LNCaP) and negative patients.
Discussion
The detection of circulating tumour cells in cancer patients is
not by any means a new phenomenon. Indeed, severalCirculating PSA-positive cells in prostate cancer
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Figure 1 (a) Scatter analysis of samples prepared by density gradient centrifugation. Lymphocytes and monocytes were identified by
conventional forward (FSC) and side (SSC) scatter with contaminating granulocytes at less than 3% of cells (A) compared with 23% in B.
(b) Dual parameter displays show MAb fluorescence (FITC) vs side scatter for the isotype control (C), PSA-stained cells (D) and LCA-
stained cells (E).
previous studies, some dating back over half a century, have
elegantly demonstrated the presence of circulating malignant
cells in the peripheral blood ofpatients with advanced disease
(Warren and Gates, 1936; Engell, 1955; Fidler, 1970; Schwartz
et al., 1995), without the help of current sophisticated and
molecular biology techniques. Previous studies in animals
have shown that metastasis does not rely on the random
survival of cells released from the primary tumour, but from
the selective growth of specialised subpopulations of highly
metastatic cells endowed with properties which will allow
them successfully to complete each step of the metastatic
cascade (Fidler, 1970; Fidler and Kripke, 1977). Based on
these principles of tumour metastasis, it has been our
intention to isolate circulating tumour cells from patients
with clinically undetectable metastases for two purposes:
firstly, to identify a group ofpatients with metastatic potential
before the firm establishment of secondary deposits, thus
allowing early aggressive treatment, and secondly, to isolate
the selected survivor tumour cell escaping into the circulation
in order to compare its biological and genetic properties with
cells from the primary tumour. Analytical FC and tissue-
specific MAb staining have been used successfully to detect
circulating PSA-positive cells in patients with prostate cancer.
However, some doubt arose as to whether the cells were solely
of prostatic origin (Hamdy et al., 1992), and the purpose of
the present study was to identify the phenotype of circulating
PSA-positive cells, confirming or excluding their prostatic
origin by detecting mRNA expression for PSA. Moreno et al.
(1992) in a similar study, have demonstrated the ability of
RT -PCR to detect haematogenous micrometastases in
patients with advanced prostate cancer, but failed to detect
any of these cells in patients with clinically non-metastatic
disease. Katz et al. (1994), also using RT-PCR, have been
able to detect circulating prostate cells in patients with
apparently localised disease undergoing radical prostatect-
omy, and found a strong correlation between a positive PCR
reaction, capsular tumour penetration and positive surgical
margins, suggesting the potential of this technique to be used
for 'molecular staging' ofprostate cancer. Two further studies
by Israeli et al. (1994, 1995) used nested RT-PCR to
compare the sensitivity of PSA with prostate-specific
membrane antigen (PSMA) in the detection of circulating
prostatic cells. The studies showed that PSMA was
significantly more sensitive than PSA, but the group could
not reproduce the results reported by Katz et al. (1994) in that
they failed to detect with any significance the presence of
micrometastatic prostatic cells in patients with pathologically
organ-confined disease. In turn, Cama et al. (1995) repeated
the initial experiments made by Katz et al. (1994) using the
same patients' samples, comparing PSA with PSMA, and
found, in contrast with Israeli et al. (1995) that PSA was more
sensitive than PSMA in predicting local tumour penetration,
adding further controversy to the possible value of these
sensitive assays in staging prosate cancer. It is interesting to
a
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Figure 2 (a) Southern blotting depicting detection of PSA. Lane 1, Molecular weight markers; lane 2, female PBMC negative
control; lanes 3 and 4, LNCaP cell line positive control; lanes 5-8, RT -PCR-negative patients; lanes 9-11, patients with benign
prostatic hyperplasia (BPH). (b) Southern blotting depicting detection of PSA. Lane 1, molecular weight markers; lanes 2-4, RT-
PCR-negative patients; lane 5, RT-PCR-positive patient; lane 6, RNA control; lane 7, cDNA control; lane 8, PCR control; lanes
9- 11, BPH tissue-positive control.
note that the authors of all these studies assume that
circulating PSA-positive cells are endowed with metastatic
propensity, despite the fact that the results only demonstrate
the presence ofcells ofprostatic origin. Furthermore, the high
sensitivity of some assays using the nested primer PCR
technique, resulting in an improved detection rate ofprostatic
cells from one per 10 000 to one per million cells may interfere
with the ability of these tests to identify cells of genuine
prostatic origin. The specificity of PSA mRNA in detecting
true prostatic cells has been questioned in a recent study by
Smith et al. (1995). Using the nested primer PCR method, the
authors demonstrated the presence of PSA mRNA in non-
prostatic cell lines, including ovarian, lung, myeloid leukaemia
and normal blood; an important observation which must be
taken into consideration when interpreting results generated
by these sensitive methods. In our positive controls, we
observed expression of two extra bands by both LNCaP cells
and tissue extracts, as illustrated in Figure 1. These bands
remain to be identified, but one could speculate that they may
represent spliced variants of PSA. The present study did not
attempt to verify the validity of the PSA RT-PCR assay nor
its sensitivity and specificity in the detection of extracapsular
prostate cancer. Should further studies confirm the malignant
nature of these circulating cells, more extensive work would
be required to assess their metastatic capability. Although our
study failed to characterise the phenotype ofcirculating PSA-
positive cells detected by FC, and despite the small number of
patients investigated, our findings whereby PSA mRNA was
detected in only one ofnine men (11.1%) with prostate cancer
and circulating PSA-positive cells, supports our initial
hypothesis that the majority of these cells are not ofprostatic
origin, but represent a population of cells which express PSA
at the cell surface. Whether circulating PSA-positive cells are
mononuclear phagocytes which have phagocytosed circulating
tumour cells and re-expressed PSA, or whether PSA has
passively adhered to the surface ofthese immunocytes remains
to be established. This hypothesis warrants clarification by
further experimentation into the cellular origin of the non-
prostatic PSA-positive cells in the blood stream of prostate
cancer patients. Studies we are currently undertaking may
reveal novel mechanisms of PSA handling by the immune
system, and allow us to improve our understanding of the
biology of prostate cancer.
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